1. Home
  2. PARK vs INO Comparison

PARK vs INO Comparison

Compare PARK & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Park Dental Partners Inc.

PARK

Park Dental Partners Inc.

HOLD

Current Price

$18.50

Market Cap

94.5M

Sector

Health Care

ML Signal

HOLD

Logo Inovio Pharmaceuticals Inc.

INO

Inovio Pharmaceuticals Inc.

HOLD

Current Price

$1.02

Market Cap

100.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PARK
INO
Founded
1972
1979
Country
United States
United States
Employees
1212
N/A
Industry
Misc Health and Biotechnology Services
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
94.5M
100.4M
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
PARK
INO
Price
$18.50
$1.02
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$6.75
AVG Volume (30 Days)
22.5K
1.5M
Earning Date
05-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
54.18
EPS
N/A
N/A
Revenue
N/A
$42,220,086.00
Revenue This Year
$7.06
$20,156.19
Revenue Next Year
$6.17
$421.95
P/E Ratio
$6.47
N/A
Revenue Growth
N/A
19.37
52 Week Low
$12.29
$0.96
52 Week High
$22.68
$2.86

Technical Indicators

Market Signals
Indicator
PARK
INO
Relative Strength Index (RSI) 46.65 35.35
Support Level $18.81 N/A
Resistance Level $21.06 $1.24
Average True Range (ATR) 1.29 0.06
MACD -0.15 -0.02
Stochastic Oscillator 17.29 19.95

Price Performance

Historical Comparison
PARK
INO

About PARK Park Dental Partners Inc.

Park Dental Partners Inc is a dental resource organization (DRO) operating through its subsidiary. It Provides comprehensive business support services including clinical team members, administrative personnel, facilities and equipment to its affiliated general and multi-specialty dental practices throughout Minnesota and Wisconsin. Its network of affiliated dental practices provides both general and specialty dental services, including oral surgery, periodontics, pediatric dentistry, prosthodontics, endodontics, and orthodontics, under long-term agreements with initial terms of 30-years, with automatic 5-year renewals.

About INO Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.

Share on Social Networks: